HomeCompareCSPCY vs DIVO

CSPCY vs DIVO: Dividend Comparison 2026

CSPCY yields 2.60% · DIVO yields 6.49%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CSPCY wins by $907.3K in total portfolio value· pulled ahead in Year 3
10 years
CSPCY
CSPCY
● Live price
2.60%
Share price
$4.61
Annual div
$0.12
5Y div CAGR
65.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$938.0K
Annual income
$630,692.19
Full CSPCY calculator →
DIVO
DIVO
● Live price
6.49%
Share price
$44.85
Annual div
$2.91
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$30.7K
Annual income
$981.68
Full DIVO calculator →

Portfolio growth — CSPCY vs DIVO

📍 CSPCY pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodCSPCYDIVO
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, CSPCY + DIVO cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
CSPCY pays
DIVO pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CSPCY
Annual income on $10K today (after 15% tax)
$221.26/yr
After 10yr DRIP, annual income (after tax)
$536,088.36/yr
DIVO
Annual income on $10K today (after 15% tax)
$552.00/yr
After 10yr DRIP, annual income (after tax)
$834.43/yr
At 15% tax rate, CSPCY beats the other by $535,253.93/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CSPCY + DIVO for your $10,000?

CSPCY: 50%DIVO: 50%
100% DIVO50/50100% CSPCY
Portfolio after 10yr
$484.4K
Annual income
$315,836.94/yr
Blended yield
65.21%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CSPCY buys
0
DIVO buys
0
No recent congressional trades found for CSPCY or DIVO in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricCSPCYDIVO
Forward yield2.60%6.49%
Annual dividend / share$0.12$2.91
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR65.6%0%
Portfolio after 10y$938.0K$30.7K
Annual income after 10y$630,692.19$981.68
Total dividends collected$886.9K$8.2K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: CSPCY vs DIVO ($10,000, DRIP)

YearCSPCY PortfolioCSPCY Income/yrDIVO PortfolioDIVO Income/yrGap
1$11,131$431.06$11,349$649.42$218.00DIVO
2$12,653$742.60$12,833$688.83$180.00DIVO
3← crossover$14,845$1,306.42$14,459$727.90+$386.00CSPCY
4$18,256$2,372.19$16,238$766.49+$2.0KCSPCY
5$24,049$4,515.02$18,179$804.47+$5.9KCSPCY
6$34,938$9,205.02$20,293$841.71+$14.6KCSPCY
7$58,080$20,696.38$22,591$878.14+$35.5KCSPCY
8$115,393$53,247.73$25,087$913.65+$90.3KCSPCY
9$287,202$163,731.68$27,791$948.18+$259.4KCSPCY
10$937,999$630,692.19$30,718$981.68+$907.3KCSPCY

CSPCY vs DIVO: Complete Analysis 2026

CSPCYStock

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Full CSPCY Calculator →

DIVOETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →
📬

Get this CSPCY vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CSPCY vs SCHDCSPCY vs JEPICSPCY vs OCSPCY vs KOCSPCY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.